LONDON (ShareCast) - (Sharecast News) - Life sciences company OptiBiotix Health announced on Wednesday that its wholly-owned subsidiary, ProBiotix Health, has entered into a non-exclusive distribution agreement with Actial Farmaceutica for the distribution of its 'CholBiome' and 'CholBiome X3' products, in four new territories in the Asia-Pacific region.
The AIM-traded firm described Actial as an Italy-based holding company with three subsidiaries worldwide - CD Pharma India, Actial APAC, and VSL Pharmaceuticals, focussed on the development of probiotic bacteria to improve gut health.

It said Actial is the developer and originator of "one of the world's best-known" probiotic brands, VSL#3.

The agreement granted Actial the right to distribute ProBiotix's cholesterol and blood pressure-reducing dietary supplements CholBiome and CholBiome X3 in Australia, New Zealand, Indonesia and Thailand.

It said the two products would be marketed under the VSL#3 range to hospital clinicians, general practitioners and pharmacies as probiotic dietary food supplements, for the management of high cholesterol and blood pressure.

The agreement extended ProBiotix's commercial reach of its finished dietary products containing its cholesterol-reducing 'LPLDL' strain into new territories, as a product line extension of the VSL#3 brand, the OptiBiotix board explained.

"We are pleased to announce the signing of this distribution agreement with Actial Farmaceutica as we believe cholesterol reducing probiotics like LPLDL are increasingly being seen by clinicians and health care professionals as a naturally safe and effective approach to reducing cardiovascular risk," said ProBiotix commercial director Mikkel Hvid-Hansen.

"We chose Actial due to a common interest in developing probiotics with strong science and clinical studies and their expertise in commercialising value added probiotics to major global pharmaceutical markets.

Hvid-Hansen said the company believed working with Actial, and similar partners globally, provided "the best opportunity" to expand the range of applications for LPLDL and CholBiome to a range of industry sectors.

"This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."

At 1529 BST, shares in OptiBiotix Health were down 0.99% at 50p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE